Novo Nordisk faced critical leadership changes and mounting challenges from Pharmacy Benefit Managers (PBMs) amid fierce competition in the obesity drug market. With a new CEO recently appointed, the company is also doubling down on strategic partnerships in China, aiming to innovate its research pipeline. However, questions remain about the global acceptance of clinical data from these collaborations and the sustainability of Novo’s market position.